Emergent BioSolutions (EBS) Net Cash Flow Growth (3y) (2013 - 2026)
Emergent BioSolutions (EBS) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 60.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.86% |
| Mar 31, 2026 | 38.99% |
| Dec 31, 2025 | -28.06% |
| Sep 30, 2025 | 42.95% |
| Jun 30, 2025 | 51.76% |
| Mar 31, 2025 | 32.80% |
| Dec 31, 2024 | -31.90% |
| Sep 30, 2024 | 58.25% |
| Jun 30, 2024 | 56.98% |
| Mar 31, 2024 | 23.56% |
| Dec 31, 2023 | -50.29% |
| Sep 30, 2023 | -26.26% |
| Jun 30, 2023 | -80.97% |
| Mar 31, 2023 | -159.19% |
| Dec 31, 2022 | 142.46% |
| Sep 30, 2022 | -45.06% |
| Jun 30, 2022 | -58.08% |
| Mar 31, 2022 | -96.61% |
| Dec 31, 2021 | 40.18% |
| Sep 30, 2021 | -31.82% |